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The main cellular sources ofinterleukin-S (IL-S) are T 
lymphocytes and mast cells. Recently, IL-S mRNA has 
been identified in eosinophils from patients with celiac 
disease, eosinophilic heart diseases, and asthma. In an 
attempt to determine whether IL-S is generated by eo-
sinophils in atopic dermatitis we have used i) in situ 
hybridization with 35S-labeled IL-S RNA probe com-
bined with immunohistochemistry using a monoclo-
nal antibody (MoAb) (EG2) directed against the acti-
vated form of Eosinophil Cationic Protein (ECP) and 
I nterleukin (IL)-5 exerts a wide range of effects on eosino-phils. IL-5 selectively induces eosinophil differentiation [1] , and enhances chemotaxis [2], cytotoxicity [3] , and survival [4] . However,·the cellular source ofIL-5, especially in tissues from patients with eosinophilic infiltration, remained to be 
elucidated. Human type 2 T helper (Th2) clones are the main cellu-
lar source of IL-5 [5] and it was also demonstrated that mouse mast 
cell lines expressed mRNAs encoding Th2 cytokines, including 
IL-5, after cross-linkage ofFceRI [6]. Recently, it has been reported 
that eosinophils have the potential to produce IL-5 . IL-5 mRNA 
was expressed by eosinophils infiltrating the intestinal mucosa of 
patients with active coeliac disease as well as by blood eosinophils 
from patients with hypereosinophilic syndrome [7,8] . In asthma, 
bronchoalveolar-Iavage eosinophils expressed IL-5 mRNA only 
after allergen challenge [9]. In this paper, we demonstrated the 
presence of both IL-5 mRNA and IL-5 immunoreactive protein in 
activated eosinophils within the lesions of patients witli atopic der-
matitis (AD). 
MATERIALS AND METHODS 
Study Subjects Biopsy specimens were obtained from the active lesions 
located on the arms of six patients with severe chronic AD diagnosed by 
the criteria of Hanifin and Rajka [10], after informed consent. The pa-
tients had not taken oral steroids for at least 1 month before the study and 
only corticoid-free ointments were allowed 1 week prior to the study. All 
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ii) double-immunostaining with anti-IL-S MoAb and 
polyclonal anti-ECP antibody. We found that dermal 
eosinophils from lesional atopic dermatitis skin ex-
press IL-S mRNA and protein. Moreover, highly puri-
fied blood eosinophils were also labeled with anti - IL-
S antibodies. The expression of IL-S by eosinophils in 
atopic dermatitis might suggest an autocrine pathway 
of eosinophil differentiation and activation. Key words: 
interleukin-S /eosinophil cationic protein/type 2 T helper 
clones.] Invest DermatoI103:589-592, 1994 
patients had elevated blood eosinophil and total immunoglobulin (Ig)E 
levels (Table I) . The biopsies were snap-frozen and stored at -80·C until 
use. 
Combination of In Situ Hybridization and Immunohistochem-
istry Ten-micrometer-thick cryostat sections were fixed in 4% para-
formaldehyde/phosphate-buffered saline (PBS), and then incubated with 
EG2, a mouse monoclonal antibody (MoAb) that recognizes the secreted 
form of eosinophil cationic protein (Eep) (kindly given by Dr. Po-Chun 
Tai, St. George's Hospital Medical School , London, UK) [11], diluted at 
16 )Lg/ m1 in PBS with 0.04% diethylpyrocarbonate at 4 · C overnight. After 
washing, the sections were incubated with anti-mouse IgG antibodies 
(Biosys, Compii:gne, France, 1:50) at room temperature (RT) for 30 min, 
and then with alkaline phosphatase anti-alkaline phosphatase (APAAP) 
(DAKO, Glostrup, Denmark, 1 :50) at RT for 30 min and developed by N ew 
Fuchsin kit (DAKO). Between each step, the sections were rinsed in steri-
lized PBS. Preparation of 35S-labeled IL-5 RNA probes (antisense probe 
and sense probe) and in sitll hybridization were performed as described be-
fore [7]. 
Double lmmunostaining The cryostat sections were fixed in 4% para-
formaldehyde and washed in 0.05 M T ris-HCl buffered isotonic saline, pH 
7.6 (TBS). After saturation with 10% normal goat serum, the sections were 
incubated with anti-human IL-5 MoAb (a gift from Dr. J an Tavernier, 
Roche Research Gent, Gent, Belgium) diluted at 20llg/mi overnight at 
4 · C, and fo llowed by the APAAP method as described above. After devel-
opment, the sections were incubated with polyclonal anti-ECP (a gift from 
Dr. Po-Chun T ai, St. George's Hospital Medical School, London, UK, 1 :50) 
for 2 h at RT, and then treated with fluorescein isothiocyanate (FITC)-con-
jugated anti-rabbit IgG (Cappel Laboratories, Cochranville, PA, 1 :50) for 1 
h at RT. Between each incubation step, the sections were washed in TBS. As 
a negative control , irrelevant MoAb (anti-p30 of Toxoplasma) was substi-
tuted for anti-IL-5 MoAb. A double immunostaining was performed in a 
similar fas hion, with polyclonal anti - IL-5 antibody (Ab) (DAKO, 1:100) 
and anti-human CD3 MoAb-FITC conjugate (20 )Lg/mI, DAKO). The 
polyclonal anti - IL-5 Ab (DAKO, 1:100) was also used to detect the pres-
ence of immunoreactive IL-5 protein on cytocentrifuged preparations of 
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Table I. Presence ofIL-5 mRNA and IL-5 Protein in the Lesions of Patients with Atopic Dermatitis 
Eo in PB' (fmm3) IgE Levels (kUI/I) Eo infilb (fHMF) IL5 mRNA(+) Eo IL-5(+) Eo 
AD-1 1,200 > 5000 3.5 ± 1.9 (-) (+) 
AD-2 600 > 5000 16.5 ± 2.3 (+) (+) 
AD-3 2,400 > 5000 6.5 ± 0.7 (-) (+) 
AD-4 2,000 > 5000 0.5 ± 0.5 (+) (+) 
AD-5 2,800 547 1.0 ± 0.8 (-) (-) 
AD-6 1,800 >5000 8.0 ± 1.2 (+) (+) 
• Eosinophils in peripheral blood. 
'Eosinophil infiltration in the skin lesions: the numbers were average ± SEM of30 fields at high magnification in the sections stained with carbol chromotropc 2R. HMF, high 
magllifi.cation field. 
purified blood eosinophils. As control, a normal rabbit serum was used under 
the same conditions. 
Eosinophil Purification Procedure Eosinophils were purified from the 
blood of one patient (AD-6), by centrifugation on discontinuous metriza-
mide gradients as previously described [7). Activated hypodense eosinophils, 
which sediment in the low-density layers, were collected. After washing, 
purified eosinophils were resuspended in HBSS culture medium alone, 
without fetal bovine serum (FBS), at a concentration of 106 cells/ml and 
loaded on slides (105 cells/slide). The cytopreparations were immediately 
fixed for 20 min in 4% paraformaldehyde and stored at 4 ' C before being 
analyzed by immunohistochemistry. 
RESULTS 
Combination of in situ hybridization with 35S-labeled antisense lL-5 
and EG2 staining showed that activated eosinophils expressed lL-5 
mRNA in the dermis of three (AD-2, AD-4, and AD-6) of six 
patients with AD (Table I). The results of patient AD-2 are shown 
in Fig 1. More than 70% of EG2-positive cells expressed strong 
positive signals ofIL-5 mRNA (Fig 1a). In addition, EG2-negative 
mononuclear cells also showed positive signals (Fig 1a). With the 
control sense probe, positive signals were not seen in either 
EG2-positive or -negative cells (Fig 1b). 
To ascertain the translation ofIL-5 mRNA in eosinophils, double 
immunostaining with anti - IL-5 and anti-ECP antibodies was per-
formed. Around 50% cells stained with anti-IL-5 MoAb (Fig 1c) 
were also stained by anti-ECP (Fig 1t1) (patient AD-3) . Sections 
incubated with control MoAb showed no positive alkaline phos-
phatase staining. Eosinophils with immunoreactive IL-5 were ob-
served in the lesions of five of six patients (Table I). IL-5 protein 
accu.mulated in ECP-negative mononuclear cells in all patients. 
Double immunostaining performed with FITC-labeled MoAb to 
CD3 and polyclonal anti-IL-5 Ab revealed by immunophosphatase 
indicated that IL-5-positive mononuclear cells were T cells (data 
not shown). 
Not only tissue cells but also highly purified blood eosinophils 
produced the IL-5 protein. As shown in Fig 1e (patient AD-6), a 
heterogeneous cytoplasmic staining was observed in 60% eosino-
phils when the control was negative (Fig 1f). 
DISCUSSION 
Our results indicate the synthesis ofIL-5 by activated eosinophils in 
the lesions of AD, raising the possibility that autocrine expression of 
IL-5 by eosinophils might prolong their survival and enhance their 
effector function. IL-5 protein was detected in dermal eosinophils 
from five of six patients, whereas IL-5 mRNA was observed in three 
patients. One possible explanation could be the short lifespan of 
IL-5 mRNA (12]. It must be noted that the biopsies from all patients 
under study were obtained from chronic lesions with acute exacer-
bation. The role of IL-5 in enhancement of eosinophil release of 
granule proteins [13], as well as in chemotaxis and survival, might 
indicate the possible involvement of this activation mechanism in 
both the acute and chronic stages of the disease. Further compara-
tive experiments on larger series of patients at different stages are in 
progress to establish the relevance of these findings with this skin 
disorder. 
In our study, eosinophils of one patient (AD-5) did not express 
either IL-5 mRNA or IL-5 protein. Interestingly, blood IgE levels 
of this patient were 10 times lower than in the other patients. One 
of the pathways leading to the expression ofIL-5 mRNA by eosino-
phils might be Ig-dependent stimulation. A recent in vitro study 
showed that IgA and IgE immune complexes were potent activators 
of IL-5 secretion [14]. Moreover, recently it has been shown that 
dermal eosinophils from active lesions of AD express the high-af-
finity IgE receptor FeeRi [15]. In this patient (AD-5) with low 
serum IgE levels, tissue IgE antibodies might be insufficient or in an 
inappropriate form to induce IL-5 secretion by eosinophils. Indeed, 
in AD, allergens have been demonstrated to activate IgE-bearing 
macrophages in an IgE-dependent manner [16] and the presence of 
IgE-bearing Langerhans cells is related to the serum IgE level [17]. 
In our study, the eosinophil was not the only cell type in the dermis 
to express lL-5 mRNA and protein, as CD3+ mononuclear cells 
were also positive. These results are in agreement with a recent 
report showing that in the late-phase cutaneous reaction to aller-
gens, only CD3+- and major basic protein (MBP) - positive cells 
expressed IL-5 [18] . It is interesting to note that not only skin 
eosinophils but also a high proportion of peripheral blood eosino-
phils express IL-5 - immunoreactive protein in the absence of ex vivo 
stimulation. These findings indicate that tissue and blood eosino-
phils can produce the IL-5 protein. 
As far as the pathogenetic role of eosinophils in AD is concerned, 
there are increasing data supporting the concept of their active par-
ticipation [19 - 21]: high eosinophil counts are common in AD; 
MBP and ECP serum levels are increased and correlate with the 
disease activity; peripheral blood eosinophils are in a pre-activated 
state leading to an increased migratory responsiveness to various 
chemotaxins [22] and an increased in vitro production of oxygen 
radicals upon stimulation with IL-5 [23]; eosinophilia is the most 
sensitive blood element to treatment with interferon y and cyclo-
sporin A significantly reduced the number ofEG2+ cells in lesional 
skin [24]; significant deposits of eosinophil-derived mediators such 
as MBP can be detected in lesional skin; activated eosinophils appear 
and release part of their granular contents in the skin of patients 
with AD after a patch-test reaction with aeroallergens. Further-
more, the expression of FeeRI on infiltrated eosinophils in lesional 
skin in AD [14] raises the hypothesis that eosinophils could present 
IgE-bound allergens, as in the case of Langerhans cells (25]. Our 
present study further supports eosinophil involvement in AD. The 
expression of IL-5 by eosinophils in peripheral blood as well as at 
sites of inflammation may provide an important autocrine pathway 
involved in local eosinophil recruitment and activation. The syn-
thesis of their own activating factors might explain the propagation 
and chronicity of lesions in diseases associated with eosinophilic 
infiltration, such as AD . 
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